357 related articles for article (PubMed ID: 18772115)
1. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.
Shaked Y; Henke E; Roodhart JM; Mancuso P; Langenberg MH; Colleoni M; Daenen LG; Man S; Xu P; Emmenegger U; Tang T; Zhu Z; Witte L; Strieter RM; Bertolini F; Voest EE; Benezra R; Kerbel RS
Cancer Cell; 2008 Sep; 14(3):263-73. PubMed ID: 18772115
[TBL] [Abstract][Full Text] [Related]
2. Redefining the target again: chemotherapeutics as vascular disrupting agents?
Gokmen-Polar Y; Miller KD
Cancer Cell; 2008 Sep; 14(3):195-6. PubMed ID: 18772108
[TBL] [Abstract][Full Text] [Related]
3. Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.
Shaked Y; Tang T; Woloszynek J; Daenen LG; Man S; Xu P; Cai SR; Arbeit JM; Voest EE; Chaplin DJ; Smythe J; Harris A; Nathan P; Judson I; Rustin G; Bertolini F; Link DC; Kerbel RS
Cancer Res; 2009 Oct; 69(19):7524-8. PubMed ID: 19738066
[TBL] [Abstract][Full Text] [Related]
4. Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells.
Taylor M; Billiot F; Marty V; Rouffiac V; Cohen P; Tournay E; Opolon P; Louache F; Vassal G; Laplace-Builhé C; Vielh P; Soria JC; Farace F
Cancer Discov; 2012 May; 2(5):434-49. PubMed ID: 22588881
[TBL] [Abstract][Full Text] [Related]
5. Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatment.
Starlinger P; Brugger P; Schauer D; Sommerfeldt S; Tamandl D; Kuehrer I; Schoppmann SF; Gnant M; Brostjan C
Neoplasia; 2011 May; 13(5):419-27. PubMed ID: 21532882
[TBL] [Abstract][Full Text] [Related]
6. Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis.
Francia G; Shaked Y; Hashimoto K; Sun J; Yin M; Cesta C; Xu P; Man S; Hackl C; Stewart J; Uhlik M; Dantzig AH; Foster FS; Kerbel RS
Mol Cancer Ther; 2012 Mar; 11(3):680-9. PubMed ID: 22188817
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients.
Cattin S; Fellay B; Pradervand S; Trojan A; Ruhstaller T; Rüegg C; Fürstenberger G
Oncotarget; 2016 Mar; 7(10):11137-50. PubMed ID: 26840567
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.
Lin YC; Liu CY; Kannagi R; Yang RB
Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1202-1215. PubMed ID: 29545238
[TBL] [Abstract][Full Text] [Related]
9. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models.
Daenen LG; Shaked Y; Man S; Xu P; Voest EE; Hoffman RM; Chaplin DJ; Kerbel RS
Mol Cancer Ther; 2009 Oct; 8(10):2872-81. PubMed ID: 19825805
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth inhibitor (VEGI; TNFSF15) inhibits bone marrow-derived endothelial progenitor cell incorporation into Lewis lung carcinoma tumors.
Liang PH; Tian F; Lu Y; Duan B; Stolz DB; Li LY
Angiogenesis; 2011 Mar; 14(1):61-8. PubMed ID: 21188501
[TBL] [Abstract][Full Text] [Related]
11. Enhanced antitumor effect of the combination of tumstatin gene therapy and gemcitabine in murine models.
Yao B; He QM; Tian L; Xiao F; Jiang Y; Zhang R; Li G; Zhang L; Hou JM; Wang L; Cheng XC; Wen YJ; Kan B; Li J; Zhao X; Hu B; Zhou Q; Zhang L; Wei YQ
Hum Gene Ther; 2005 Sep; 16(9):1075-86. PubMed ID: 16149906
[TBL] [Abstract][Full Text] [Related]
12. Ginsenoside Rg3 attenuates tumor angiogenesis via inhibiting bioactivities of endothelial progenitor cells.
Kim JW; Jung SY; Kwon YH; Lee JH; Lee YM; Lee BY; Kwon SM
Cancer Biol Ther; 2012 May; 13(7):504-15. PubMed ID: 22406998
[TBL] [Abstract][Full Text] [Related]
13. Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy.
Paez-Ribes M; Man S; Xu P; Kerbel RS
Clin Cancer Res; 2015 Dec; 21(24):5488-98. PubMed ID: 26169967
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of accelerated tumor growth by blocking the recruitment of mobilized endothelial progenitor cells after chemotherapy.
Murakami J; Li TS; Ueda K; Tanaka T; Hamano K
Int J Cancer; 2009 Apr; 124(7):1685-92. PubMed ID: 19089911
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.
Beaudry P; Force J; Naumov GN; Wang A; Baker CH; Ryan A; Soker S; Johnson BE; Folkman J; Heymach JV
Clin Cancer Res; 2005 May; 11(9):3514-22. PubMed ID: 15867254
[TBL] [Abstract][Full Text] [Related]
16. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.
Shaked Y; Ciarrocchi A; Franco M; Lee CR; Man S; Cheung AM; Hicklin DJ; Chaplin D; Foster FS; Benezra R; Kerbel RS
Science; 2006 Sep; 313(5794):1785-7. PubMed ID: 16990548
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
[TBL] [Abstract][Full Text] [Related]
18. NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells.
Di Matteo P; Hackl C; Jedeszko C; Valentinis B; Bordignon C; Traversari C; Kerbel RS; Rizzardi GP
Br J Cancer; 2013 Jul; 109(2):360-9. PubMed ID: 23828516
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy of VEGF-trap and gemcitabine results in improved anti-tumor efficacy in a mouse lung cancer model.
Zhou S; Yang Y; Yang Y; Tao H; Li D; Zhang J; Jiang G; Fang J
PLoS One; 2013; 8(7):e68589. PubMed ID: 23874680
[TBL] [Abstract][Full Text] [Related]
20. Decursin inhibits vasculogenesis in early tumor progression by suppression of endothelial progenitor cell differentiation and function.
Jung SY; Choi JH; Kwon SM; Masuda H; Asahara T; Lee YM
J Cell Biochem; 2012 May; 113(5):1478-87. PubMed ID: 22298358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
